Download Citation
Article Source:
No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
Zhou Sw,
Huang Yy,
Wei Y,
Jiang Zm,
Zhang Yd,
et al.
(2012)
No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis.
PLOS ONE 7(11): e50925.
https://doi.org/10.1371/journal.pone.0050925